Studies on pharmacological mechanisms demonstrated that a strategy of dual renin-
angiotensin system (RAS) blockade may have a synergistic effect in the treatment of …

The renin-angiotensin system (RAS) has an important role in hypertension and the
continuum of cardiovascular and kidney disease. The inhibition of this system, either with an …

It is well-accepted that therapies directed at the renin–angiotensin system (RAS) reduce the
progression of chronic kidney disease. Angiotensin-converting enzyme (ACE) inhibitors and …

The renin–angiotensin system (RAS) plays an important role in the pathogenesis of
cardiovascular disease. One of the effects of the activated RAS is target-organ damage, in …

Despite the renoprotective effects of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II receptor blockers (ARBs), many patients with chronic kidney disease develop …

The clinical benefits of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II
receptor blockers (ARB) are well established in chronic kidney disease (CKD) patients with …

The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker
olmesartan to a combination of angiotensin-converting-enzyme inhibitors and β-blockers in …

The renin-angiotensin system (RAS) inhibition plays an important role in the therapeutic
approach of the hypertensive patient, including the prevention of cardiovascular and renal …

Circulatory and tissue renin-angiotensin systems (RAS) play a central role in cardiovascular
(CV) and renal pathophysiology, making RAS inhibition a logical therapeutic approach in …

European and United States regulatory agencies recently issued warnings against the use
of dual renin–angiotensin system (RAS) blockade therapy through the combined use of …